Please download the dossier by clicking on the dossier button x
×

Imidazoquinolines as dual lipid kinase and mTOR inhibitors

  • US 9,370,508 B2
  • Filed: 02/19/2008
  • Issued: 06/21/2016
  • Est. Priority Date: 02/20/2007
  • Status: Active Grant
First Claim
Patent Images

1. A method of inhibiting mammalian target of rapamycin (mTOR) kinase in a patient with mTOR kinase dependent disease comprising administering a therapeutically effective amount of a compound 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, or a pharmaceutically acceptable salt thereof, to a patient in need thereof wherein said mTOR kinase dependent disease is selected from the group consisting of muscle wasting, atrophy and cachexia.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×